Ingelheim, Germany, August 30, 2010 – The European Society of Cardiology (ESC) today issued revised practice guidelines for the management of atrial fibrillation (AF), including guidance on the role of a novel oral treatment, dabigatran etexilate, for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF).
A new era for patients with atrial fibrillation - Dabigatran etexilate at the forefront
- For non-US Heathcare Media and Medical Media only
Aug 30, 2010
Latest in Home
NAM Opposes New Overtime, Noncompete Rules
April 24, 2024
Tesla 1Q Profit Falls 55%
April 24, 2024
Boeing Posts $355 Million Loss
April 24, 2024